[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546421":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":33,"locations":11,"responsibleParty":39,"collaborators":11,"id":41,"slug":11,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":11,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":11,"enrollmentInfo":49,"targetDuration":11,"studyType":52,"phases":53,"briefSummary":56,"conditions":57,"keywords":11,"overallStatus":59,"whyStopped":11,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":11},{"fullName":5,"class":6},"Qilu Pharmaceutical Co., Ltd.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"QLF31907 in combination with Irinotecan","EXPERIMENTAL",null,[13,14],"Drug: QLF31907","Drug: Irinotecan",{"label":16,"type":10,"description":11,"interventionNames":17},"QLF31907 in combination with Docetaxel",[13,18],"Drug: Docetaxel",[20,25,29],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","QLF31907","intravenous administration, once every 3 weeks",[16,9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Irinotecan","intravenous administration, 125 mg\u002Fm2, d1 and d8, every 3 weeks",[9],{"type":21,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"Docetaxel","intravenous administration, 75mg\u002Fm2, d1, every 3 weeks",[16],[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Lin Shen","CONTACT","010-88196561","doctorshenlin@sina.cn",{"type":40,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100546421",false,"NCT06394713","A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors","A Phase 1b\u002F2 Trial to Evaluate the Efficacy and Safety of QLF31907 (PD-L1\u002F4-1BB Bi-specific Antibody) Combination Therapy in Patients With Advanced Malignant Tumors","Inclusion Criteria:\n\n1. subjects voluntarily participated and signed a written informed consent form;\n2. age ≥18 years, male or female;\n3. ECOG PS 0-1;\n4. histopathologically diagnosed advanced malignant tumors;\n5. at least 1 measurable lesion according to RECIST v1.1 criteria or Lugano (2014) criteria;\n6. adequate organ function;\n\nExclusion Criteria:\n\n1. previous treatment with 4-1BB agonist or 4-1BB recombinant fusion protein;\n2. received anti-tumor therapy within 4 weeks prior to the first study treatment;\n3. history of autoimmune disease;\n4. history of other active malignancies within 3 years prior to the first treatment;\n5. history of serous cardiovascular events;","ALL","18 Years",{"count":50,"type":51},60,"ESTIMATED","INTERVENTIONAL",[54,55],"PHASE1","PHASE2","This study is designed to evaluate the safety and efficacy of QLF31907 combination therapy in advanced malignant tumors.",[58],"Advanced Malignant Neoplasm","NOT_YET_RECRUITING","2024-04-29",{"date":62,"type":63},"2024-05-01","ACTUAL",{"date":65,"type":51},"2024-06-15",{"date":67,"type":51},"2026-12-15",{"name":5,"class":6}]